Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells by An, Dingding et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.cell.2013.11.042
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
An, D., Oh, S. F., Olszak, T., Neves, J. F., Avci, F. Y., Erturk-Hasdemir, D., ... Kasper, D. L. (2014).
Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell, 156(1-
2), 123-33. https://doi.org/10.1016/j.cell.2013.11.042
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
Sphingolipids from a symbiotic microbe regulate homeostasis of
host intestinal natural killer T cells
Dingding An1, Sungwhan F. Oh1, Torsten Olszak2, Joana F. Neves2, Fikri Avci1,3, Deniz
Erturk-Hasdemir1, Xi Lu4, Sebastian Zeissig2, Richard S. Blumberg2,*, and Dennis L.
Kasper1,*
1Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115,
USA
2Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA 02115, USA
3Department of Biochemistry and Molecular Biology, Center for Molecular Medicine, University of
Georgia, Athens, GA 30602, USA
4Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
02115, USA
Summary
Co-evolution of beneficial microorganisms with the mammalian intestine fundamentally shapes
mammalian physiology. Herein we report that the intestinal microbe Bacteroides fragilis modifies
the homeostasis of host invariant natural killer T (iNKT) cells by supplementing the host’s
endogenous lipid antigen milieu with unique inhibitory sphingolipids. The process occurs early in
life and effectively impedes iNKT cell proliferation during neonatal development. Consequently,
total colonic iNKT cell numbers are restricted into adulthood and hosts are protected against
experimental iNKT cell–mediated, oxazolone-induced colitis. In studies with neonatal mice
lacking access to bacterial sphingolipids, we found that treatment with B. fragilis
glycosphingolipids—exemplified by an isolated peak (M.W.=717.6) called GSL-Bf717—reduces
colonic iNKT cell numbers and confers protection against oxazolone-induced colitis in adulthood.
Our results suggest that the distinctive inhibitory capacity of GSL-Bf717 and similar molecules
may prove useful in the treatment of autoimmune and allergic disorders in which iNKT cell
activation is destructive.
Introduction
As humans, we require symbiotic microbes to establish and maintain health. Microbes
equipped with beneficial properties are preferentially granted membership in our intestinal
community. Understanding the specific molecules and immune mechanisms used by
microbes to elicit their beneficial phenotype is a key step towards informed use of the
microbiota to help resolve many health issues (Bäckhed et al., 2005; Chow et al., 2010;
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Honda and Littman, 2012). Currently, these molecules and mechanisms remain largely
unknown. One exception to this dearth of knowledge on the contribution of specific
microbial products to the host immune system is the body of literature on polysaccharide A
(PSA) (Mazmanian et al., 2005; Mazmanian et al., 2008; Round et al., 2011) produced by
the common intestinal symbiont Bacteroides fragilis.
Symbiotic bacteria possess enigmatic phenotypes that are unusual in environmental bacterial
species and pathogens. For example, bacterial sphingolipids are produced predominantly by
species in the phylum Bacteroidetes (Ingar and Erik, 2001; Kato et al., 1995), many of
which are associated almost exclusively with mammalian hosts. The only identified function
of bacterial sphingolipids is the activation of invariant natural killer T (iNKT) cells by
glycosphingolipids produced by certain soil-dwelling Sphingomonas species in the phylum
Proteobacteria—one of only a few known sphingolipid producers outside the Bacteroidetes
(Kinjo et al., 2005; Mattner et al., 2005). iNKT cells recognize non-polymorphic major
histocompatibility complex class I–like, CD1d protein–presented lipid antigens, of which
the best studied are glycosphingolipids (Cohen et al., 2009). With their remarkable ability to
quickly release high levels of cytokines upon activation (Kronenberg, 2005; Matsuda et al.,
2008), iNKT cells are critical players in innate and adaptive immunity. Previously, our
group demonstrated that specific pathogen–free (SPF) mice had lower iNKT cell numbers in
the colonic lamina propria (LP) than did germ-free (GF) mice; accordingly, SPF mice were
protected from experimental iNKT cell–mediated, oxazolone-induced colitis, whereas GF
mice were not (Olszak et al., 2012). These results suggested that sphingolipids produced by
symbiotic bacteria might play an important role in host colonic iNKT cell homeostasis and
in the oxazolone colitis susceptibility phenotype.
Results
B. fragilis sphingolipids modulate host colonic iNKT cell homeostasis and protect the host
from a colitis challenge
In the model organism B. fragilis NCTC 9343, the enzyme encoded by gene BF2461 has a
high degree of homology (E values ≤−44 by standard BLASTP search) (Altschul, 2005)
with the eukaryotic enzyme serine palmitoyltransferase (SPT). SPT, the first committed
enzyme in sphingolipid biosynthesis, produces 3-ketosphinganine from palmitoyl-CoA and
serine (Lowther et al., 2012). We knocked out gene BF2461 from wild-type B. fragilis
NCTC 9343 (BFWT) to create a mutant strain BFΔSPT, and we complemented this mutant
with a full copy of BF2461 in trans (C-delta). We found the BFWT and BFΔSPT in vitro
growth kinetics were generally comparable although BFΔSPT had a slightly longer doubling
time (64±0 min vs. 74±1 min, Fig. S1A). Using thin-layer chromatography, we compared
lipid extracts from BFWT and BFΔSPT strains and identified several spots that were present
in the former but lacking in the latter. We further treated the two samples with mild alkaline
hydrolysis to differentiate sphingolipids from phospholipids, the latter being the most
common components of bacterial lipid membranes. The spots that were unique to the BFWT
strain were indeed sphingolipids, as determined by their resistance to hydrolysis; in
comparison, the spots that were present in both strains were hydrolyzed after treatment, a
result suggesting that these spots were phospholipids. C-delta conferred the wild-type profile
of sphingolipid generation (Fig. S1B).
After mono-colonizing GF mice with either BFWT bacteria (termed BFWT mice) or
BFΔSPT bacteria (termed BFΔSPT mice), we monitored absolute and relative numbers of
iNKT cells in their pups’ colonic LP from birth to 9 weeks of age as well as in age-matched
GF and SPF mice (Figs. 1A–1C). We found that iNKT cells were absent from the colon in
all mice at birth but then were present in numbers that gradually increased until reaching
steady state at the age of 6 weeks. However, the relative (to CD3+ T cells) and absolute
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numbers of iNKT cells in GF and BFΔSPT mice were significantly higher than those in SPF
and BFWT mice, despite lower cell numbers in BFΔSPT mice than in GF mice. We also
found that colonic LP CD3+ T cell numbers were similar in GF, BFWT and BFΔSPT mice
(Fig. S1C). These results suggest that bacterial sphingolipids from a single microbe, B.
fragilis, negatively regulate iNKT cell numbers in the colon, although we do not know
whether colonic iNKT cells from the BFWT and BFΔSPT mice are functionally similar,
e.g., the same capacity for cytokine production upon activation. In addition, C-delta-mono-
associated mice had colonic iNKT cell numbers similar to those in BFWT mice (Fig. S1D).
In previous comparisons of iNKT cell numbers in SPF and GF mice, we found that SPF
animals had higher numbers in the thymus, spleen, and liver but lower counts in the colon
and lung (Olszak et al., 2012). In the current studies, we found that, despite iNKT cell
number differences in the colon, BFWT mice did not differ from BFΔSPT mice, or GF mice,
in terms of iNKT cell numbers in the lung, liver, small intestine, thymus, spleen, or Peyer’s
patches (Figs. 1D–1F and Figs. S1E–S1G). These results indicate that B. fragilis
sphingolipids exert effects on iNKT cells only in the colon, where this bacterium is most
abundant. A possible reason for the local effect of the B. fragilis glycosphingolipids in these
mice is that their quantity, stability, and/or potency are not high enough to have an effect
outside the large intestine for iNKT cell regulation.
To investigate whether the difference in colonic iNKT cells between BFWT and BFΔSPT
mice has biological significance, we subjected these mice to an oxazolone colitis challenge,
in which intestinal inflammation characteristic of human ulcerative colitis is induced and is
dependent on iNKT cell–produced interleukin 13 (IL-13) (Boirivant et al., 1998; Fuss et al.,
2004; Heller et al., 2002). As expected, BFΔSPT mice had more severe weight loss (Fig.
2A), higher cumulative histopathology scores (Fig. 2B), and higher levels of IL-13 and
interleukin 4 (IL-4) release than BFWT mice, although the difference was not significant in
interleukin 1β (IL-1β) production (Figs. 2C–2E). Furthermore, we confirmed that the
BFΔSPT mouse phenotype was CD1d-dependent: blocking of CD1d with a monoclonal
antibody (19G11) during the neonatal period reduced iNKT cell numbers and prevented the
colitis phenotype when these mice were challenged in adulthood (Fig. S2A–C). It is possible
that different functional characteristics, e.g., cytokine production during colitis stimulation,
of the iNKT cells from these two mono-associated mice may also partially contribute to the
colitis results. Nonetheless, our results showed a direct link between symbiotic bacterial
sphingolipids and both host iNKT cell homeostasis and disease susceptibility.
B. fragilis sphingolipids inhibit host colonic iNKT cell proliferation during neonatal
development
We next investigated a number of possible causes for our findings that mice mono-colonized
with BFWT and BFΔSPT had different iNKT cell homeostasis in the colonic LP. We
studied the relative numbers of BFWT and BFΔSPT bacteria contained within the colons,
including microbes that were either in the lumen or tissue-associated (Fig. S3A and B) and
we did not find appreciable differences in bacterial numbers between the two strains in any
condition tested. We next studied the ability of B. fragilis to normalize the elevated colonic
levels of CXCL16 observed in GF mice (Olszak et al., 2012) and found that the two types of
mono-colonized mice had similar cxcl16 mRNA levels in the colon tissues, comparable to
that of the GF mice (Fig. S3C). Thirdly, we analyzed the activation (Wingender et al., 2012)
(Figs. S3D) and apoptosis (Table S1) of colonic iNKT cells in BFWT and BFΔSPT mice
and found little difference. Lastly we investigated whether PSA expression was
quantitatively different in BFWT and BFΔSPT strains, which could lead to differential
activation of PSA-mediated pathways (Fig. S3E). We found that PSA production levels
were statistically identical in the two strains. Thus we discovered no evidence to support any
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of the above mechanisms accounting for the differences in iNKT cell homeostasis in mice
colonized with the BFWT vs. BFΔSPT bacteria.
One other possibility we considered was that some bacterial sphingolipids, including those
of B. fragilis, inhibit the expansion of the iNKT cell population in the colon. To test this
hypothesis, we measured the expression of Ki-67 (a nuclear protein marker for cellular
proliferation) in iNKT cells within the colonic LP of mice from birth to 9 weeks of age. We
found significantly higher mean fluorescence intensity (MFI) expression for this protein in
both GF and BFΔSPT mice than in either SPF or BFWT mice during the neonatal period,
particularly between days 5 and 12; at 8 days of age, the percentage of Ki-67+ iNKT cells
was also higher in GF and BFΔSPT mice. Proliferation was reduced to similar low levels in
all mice after 21 days (Figs. S3F, 3A and S3G). To verify this observation, we used an
alternative approach—the bromodeoxyuridine (BrdU) method—to measure DNA replication
in colonic LP iNKT cells in 8-day-old mice. We confirmed that GF and BFΔSPT mice had
higher levels of DNA replication in these cells than did SPF and BFWT mice, respectively
(Fig. S3H and 3B). These studies showed that symbiotic bacterial sphingolipids can
modulate the homeostasis of colonic iNKT cells by inhibiting cell proliferation—and thus
their accumulation—during neonatal development.
On the basis of these findings, we hypothesized that only when mice are exposed to
symbiotic sphingolipids very early in life are their iNKT cell numbers restricted in
adulthood. We designed two co-housing experiments to test this hypothesis. In the first, GF
dams were mated with BFWT monocolonized mice. Ki-67 expression in offspring pups’
colonic LP iNKT cells was measured at 8 days of age (Fig. 3C), and iNKT cell numbers
were measured at 8 weeks (Fig. 3D). As expected, proliferation levels and total cell numbers
in pups born to dams receiving BFWT bacteria [GF-WT(neo)] were similar to those in
BFWT mice. In the second experiment, we co-housed GF pups at 10–14 days of age with
BFWT mice [GF-WT(adu)], just after the cell proliferation window had closed. As
expected, although GF-WT(adu) mice harbored numbers of BFWT bacteria equivalent to
those in GF-WT(neo) mice, the GF-WT(adu) animals had much higher colonic LP iNKT
cell numbers at 8 weeks of age. When we challenged these mice with oxazolone, GF-
WT(neo) mice responded similarly to BFWT mice, with a significant reduction in the
severity of the colitis phenotype and intestinal inflammation (as assessed by weight loss and
colitis scores) from values obtained in GF-WT(adu) mice (Figs. 3E and 3F). These studies
established a critical time window for exposure to sphingolipid-producing symbionts to
maintain host iNKT cell homeostasis and influence disease susceptibility. Interestingly,
when we co-housed GF pregnant dams with BFWT mice three days before delivery, the
pups’colonic iNKT cell numbers were not normalized to the BFWT level but more
resembled the numbers found in GF mice, although at time of delivery the mother was
heavily colonized with BFWT bacteria (data not shown). This finding indicates that either
bacterial sphingolipids are important to iNKT cell development at the prenatal stage or that
as yet unidentified factors also control iNKT cell homeostasis.
Purified B. fragilis glycosphingolipids inhibit iNKT cell activation in vitro and in vivo
In order to identify bioactive sphingolipids of B. fragilis, we performed comparative
lipidomic profiling of BFWT and BFΔSPT bacteria by HPLC–tandem mass spectrometry. In
BFWT lipid extracts, we identified three types of sphingolipids with characteristic MS/MS
fragmentation patterns: ceramides (Cers), glycosylceramides (GL-Cers, signature fragments
of 161,179), and phosphoethanolamine-ceramides (PE-Cers, signature fragment of 140)
(Fig. 4A and data not shown); none of these sphingolipids was detected in BFΔSPT lipid
extracts. To determine whether any of these sphingolipids activated iNKT cells, we
conducted co-culture assays. Bone marrow dendritic cells (BMDCs) were pulsed with each
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sphingolipid type and then incubated with iNKT cell hybridoma 24.7. None of the lipids in
the tested conditions activated iNKT cells to produce appreciable interleukin 2 (IL-2),
although the prototypical ligand KRN7000 caused robust activation (Fig. 4B). We next
tested whether these lipids were inhibitory to iNKT cells. We pulsed BMDCs with each
sphingolipid type in the presence of KRN7000 and then incubated the cells with hybridoma
24.7, measuring the production of IL-2 as an indicator of iNKT cell activation; 100%
activation was defined by the level of IL-2 production in the KRN7000 alone condition. In
this assay, GL-Cers, but not the other two lipid types, significantly reduced iNKT cell
activation by KRN7000 (Fig. 4C). It is very likely that the difference in activity among the
three classes of lipid molecules lies in the different head groups. Most probably the hexose
head group allows molecules in the GL-Cers fraction to interact more stably with CD1d and/
or iNKT cells compared to phosphoethanolamine and hydrogen head groups in PE-Cers and
Cers fractions, respectively.
To identify molecules inhibitory to iNKT cell activation, we further analyzed the GL-Cers
cluster. We found that GL-Cers is composed of multiple molecular species, ranging from m/
z 688 to m/z 744 (Fig. 4D). The observation that all species had characteristic fragments at
m/z 143, 161, and 179, which were from the hexose head group, implied the source of the
structural variability resided in the chain length of ceramide structures from C32 to C36
(Fig. 4E and data not shown). Tandem mass spectrometric analysis of a prominent m/z 716
peak (C34: M.W.=717.6) generated multiple daughter ions—assigned as m/z 698 ([M-H-
H2O]), 680 ([M-H-2H2O]), 554 ([M-H-hexose+H2O]), 536 ([M-H-hexose]), and 490 ([M-
H-C15H29O])—in addition to the above-mentioned hexose-derived fragments. Among these
daughter ions, m/z 490 (loss of the hydroxyl aliphatic chain) assigned that sphingosine and
fatty acid chain has one hydroxyl group each (Fig. 4E). The m/z 716 peak was purified by
HPLC and further analyzed. By high-pH anion-exchange chromatography (HPAEC), we
identified the structure of the monosaccharide head group as galactose (Fig. 4F). In addition,
we used 1H-NMR (Fig. 4G) and 1H-1H-NMR (COSY, data not shown) to verify the identity
of the hexose and characterize its glycosidic linkage. NMR analysis revealed a galactose
residue linked α-glycosidically to the sphingoid backbone. This α-galactosylceramide peak
is referred to as GSL-Bf717; a proposed molecular configuration is shown in Fig. 4H. In
addition, we confirmed that GSL-Bf717 was detectable only in fecal samples from BFWT
mice but not in samples from BFΔSPT mice. The estimated yield of GSL-Bf717 was ~1 ng
per gram of fecal pellet. Although it shares key features with known iNKT cell agonist
KRN7000, GSL-Bf717 has unique structural characteristics, such as shorter chain lengths
and different hydroxyl compositions in both chains. Ceramides produced by B. fragilis are
known to have branched acyl chains in iso- or anteiso- positions (Miyagawa et al., 1979),
which may present yet another distinction between GSL-Bf717 and KRN7000. As a result
of these dissimilarities, GSL-Bf717 may possibly compete with KRN7000 for the limited
space in CD1d grooves but may be positioned differently so that the α-galactosyl head
group does not interact with the iNKT cell receptor in the same way as KRN7000. It is
unclear whether GSL-Bf717 and similar molecules are presented as antagonistic ligands or
simply occupy the CD1d binding space due to high affinity. In either case the end
consequence is that these bacterial glycosphingolipids and KRN7000 have opposing
immunological effects; GL-Cers restrains iNKT cell activation and KRN7000 activates
iNKT cells.
To confirm that GSL-Bf717 has inhibitory activity, we performed several co-culture assays.
In co-cultures of BMDCs and iNKT cell hybridoma 24.7, GSL-Bf717 did not activate iNKT
cells (Fig. 5A). Moreover, GSL-Bf717 did not activate non-invariant NKT cell line 14S6
(data not shown). We next conducted a CD1d-loading experiment using phycoerythrin-
stained CD1d empty tetramers and the iNKT cell hybridoma 24.7. When the empty CD1d
tetramers are loaded with lipid antigens, they can bind to the iNKT cell receptor and the
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complex can be detected by flow cytometry, as shown in Figs. S4A–S4D for tetramers either
pre-loaded at the NIH facility (Fig. S4B) or lab-loaded (Fig. S4D) with PBS-57 (a lipid
variant of KRN7000 that also stimulates iNKT cells). Previously empty tetramers added
with either one of the three identified lipid fractions (Fig. 4A) or GSL-Bf717 did not bind to
iNKT cells (Figs. S4E–S4H). In addition, GSL-Bf717-added, previously empty CD1d
tetramers did not effectively stain liver lymphocytes in contrast to the control tetramers
loaded with PBS-57 (Figs. S4I–S4K). These CD1d-loading experiments provide supporting
evidence that the purified bacterial lipids do not activate 24.7 iNKT hybridoma cells in the
tested conditions. The likely mechanisms could be either that the lipids do not sit or do not
sit correctly in the CD1d binding grooves and/or that the iNKT TCRs do not recognize these
CD1d-lipid complexes.
When in competition with KRN7000 at a ratio of 1:30 in the co-culture assay using BMDCs
and 24.7 cells, GSL-Bf717 in excess moderately (i.e., by 40%) inhibited KRN7000-induced
activation of iNKT cells (Fig. 5B, left group of columns). This limited suppressive activity
of GSL-Bf717 suggested that it likely acts as a competitive inhibitor to agonists in binding
to CD1d, instead of as a true antagonist. However, when we tested another iNKT cell
agonist, β-glucosylceramide (β-GlcCer, d18:1/24:1(15Z)), we found that GSL-Bf717 was
more effective in inhibiting its function. β-GlcCer is an endogenous agonist that has much
weaker activity than KRN7000 (Brennan et al., 2011). Indeed, in our assay, to induce
comparable IL-2 production in the 24.7 hybridoma, it took micromolar concentrations of β-
GlcCer as compared to nanomolar concentrations of KRN7000 (Fig. 5A). Remarkably,
GSL-Bf717 not only could inhibit β-GlcCer function in a dose-dependent fashion, but also
could achieve about 40% inhibition with as little as 2.5% of the β-GlcCer concentration (Fig.
5B, right group of columns, 40:1). We next used the hybridoma DN32.D3 to test the
inhibitory activity of GSL-Bf717 on KRN7000 function. We found that GSL-Bf717 was not
able to activate this iNKT cell line when using BMDC as the CD1d-expressing antigen
presenting cell, but could inhibit iNKT cell activation by KRN7000 to a similar extent as in
24.7 (Fig. 5C and 5D). As seen with hybridoma 24.7, Cers could not inhibit DN32.D3 iNKT
hybridoma cell activation by KRN7000. Comparison of Figs. 4C and 5B shows that the GL-
Cers fraction was a more potent inhibitor of iNKT cell activation than was GSL-Bf717. It is
highly likely that many B. fragilis glycosphingolipid species can additively or
synergistically inhibit iNKT cells just as GSL-Bf717 does. Nonetheless, GSL-Bf717 is
representative of these glycosphingolipids and can be used to further explore the inhibitory
activity of GL-Cers.
To understand at the molecular level the inhibitory activity of GSL-Bf717, we performed a
CD1d tetramer competitive loading experiment. We incubated PBS-44 (another variant of
KRN7000 that is also agonistic to iNKT cells and can be efficiently loaded to empty CD1d
tetramers) with phycoerythrin-labeled unloaded CD1d tetramers in the presence and absence
of GSL-Bf717 in 1:1:3 ratio (tetramers: PBS-44: GSL-Bf717). We then used the CD1d-lipid
complex to stain an excess number of iNKT hybridoma 24.7 cells and measured MFI. We
found that in comparison to the PBS-44+vehicle control, addition of GSL-Bf717 to PBS-44
was able to significantly reduce the MFI of the stained iNKT cells to about 57% of the
vehicle control, reflecting the decreased staining efficiency of the tetramers, as well as the
poor loading capacity of PBS-44 to CD1d in presence of GSL-Bf717 (Fig. 5E). This
experiment strongly suggested that the inhibitory function of GSL-Bf717 was likely
mediated at the molecular level during CD1d-lipid interactions where GSL-Bf717 could
either occupy the CD1d grooves and prevent PBS-44 loading, and/or that GSL-Bf717-
loaded CD1d complex was not recognized properly by the iNKT cells (thus decreased MFI).
To investigate whether GSL-Bf717 inhibits iNKT cell agonist function in vivo, we
intraperitoneally injected KRN7000 (100 ng) and GSL-Bf717 (1000 ng) into mice and
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measured serum interferon-γ (IFN-γ) and IL-4 production 4 hours later. When administered
with GSL-Bf717, the ability of KRN7000 to produce both cytokines in serum was
significantly reduced compared to that of KRN7000 alone; in contrast, PE-Cers at the same
dose co-administered with KRN7000 did not reduce production of either cytokine (Figs. 5F
and 5G). In this experiment, the production of these cytokines through KRN7000
stimulation was mediated by iNKT cells and dependent on CD1d expression: no IFN-γ or
IL-4 was detected in CD1d-knockout mice in any group (data not shown). These results
demonstrated that GSL-Bf717 inhibits agonist-induced iNKT cell activation in vivo.
GSL-Bf717 treatment of BFΔSPT mice restores colonic iNKT cell homeostasis and
protects mice from colitis
Endogenous lipids provide important antigens that drive in vivo activation of iNKT cells
(Brennan et al., 2011; Rossjohn et al., 2012). Our studies with KRN7000 suggested that
GSL-Bf717 might inhibit in vivo activation and expansion of iNKT cells by endogenous
lipids during the neonatal period. We therefore administered GSL-Bf717 (100 ng/dose) five
times by gavage to newborn BFΔSPT mice at 2–7 days of age and then measured the colonic
iNKT cell Ki-67 levels at 8 days and total colonic iNKT cell numbers at 8 weeks. Compared
with vehicle-treated mice, GSL-Bf717-treated BFΔSPT mice had significantly lower levels
of Ki-67 expression at a very young age (Fig. 6A) as well as lower cell numbers in
adulthood (Fig. 6B). When challenged with oxazolone, GSL-Bf717-treated mice lost less
weight and had lower cumulative histopathology scores than did vehicle-treated mice (Figs.
6C and 6D). GSL-Bf717 is certainly not the only lipid that can mediate the above
phenotypes, it may not even be the most potent one, yet it provides proof-of-principal
evidence that bacterial glycosphingolipids can be orally administrated to susceptible hosts at
a young age to perhaps permanently limit colonic iNKT cell numbers and reduce host colitis
susceptibility into adulthood.
Discussion
Although in utero development takes place in a sterile environment, mammals commence a
lifelong relationship with microbes at birth and may be exposed to microbial products
through the placenta during gestation. Symbionts thus have the opportunity to affect host
physiology from an early age, when many host functions are actively evolving. This work
offers mechanistic data that support the growing body of evidence indicating the importance
of early-life microbial exposure in regulating adult immune homeostasis and disease
susceptibility (Isolauri, 2009; Olszak et al., 2012; Strachan, 1989). Our results reveal an
unexpected mechanism for the attainment of host immune balance: symbionts negatively
regulate a crucial immune cell type, the iNKT cell, and prevent its excessive activation
during a disease challenge. This modulation is fundamentally based on the ability of
symbionts to modify the host lipid environment by means of bacterial glycosphingolipids.
Indeed, the SPT homolog and potentially the ability to synthesize sphingolipids are well
conserved in intestinal Bacteroides species (An et al., 2011; Kato et al., 1995) and the
availability of these sphingolipids in the intestines is likely not an issue. Because of
structural similarities with iNKT cell agonists, these non-activating sphingolipids effectively
blend into the host lipid antigen pool and turn the hyper-proliferating environment during
neonatal development into a restricted one. Consequently, iNKT cell activation and
expansion caused by indigenous self and microbial stimuli are reduced. Importantly, in SPF
and BFWT mice, despite lower numbers of colonic iNKT cells in the presence of these
bacterial lipids, these cells still undergo some proliferation during the neonatal period (Fig.
3A and S3G) suggesting that the host’s endogenous agonists are still recruited to expand the
cell population in these mice. Wieland Brown et al. have very recently reported that some B.
fragilis sphingolipids can provide weak agonistic activity to iNKT cells (Wieland Brown et
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al., 2013). Since we have found that B. fragilis produces a variety of sphingolipid species, it
is not surprising that some of the lipid structures are stimulatory while others (as we are
reporting) are inhibitory. It is very important to take note of the fact we have shown in this
paper that the total net effect of these lipids, as demonstrated by comparison of the iNKT
cell numbers in colons of BFWT and BFΔSPT mice, are inhibitory to iNKT cells in the
colonic LP. GSL-Bf717 serves as a paradigm for these iNKT cell-restrictive lipids.
In our previous study comparing SPF and GF mice iNKT cells in the lung and colon, we
identified that increased CXCL16 chemokine release from these tissues was a mechanism
responsible in GF mice for the heightened iNKT cell accumulation in these tissues. In the
present study, we found that the colonic cxcl16 mRNA expression in BFWT or BFΔSPT
mice were at similarly high levels to those found in GF mice. Therefore, colonization by the
single organism B. fragilis does not down-modulate CXCL16 expression in colon tissues
and does not modify trafficking of these cells to the colon. However, the bacterial
sphingolipids in BFWT mice can restrict local proliferation of colonic iNKT cells once the
cells arrive. Ultimately, colonic iNKT cells achieve homeostasis with smaller total numbers
in BFWT mice compared to those in BFΔSPT mice or GF mice, which do not possess the
bacterial sphingolipids-mediated inhibition of proliferation. It is remarkable that mono-
colonization by a single sphingolipid-producing bacterial species, which does not have the
CXCL16 modulation capacity, can have impacts on host iNKT cell homeostasis and colitis
susceptibility comparable to those attained by the whole microbiota, which implements the
additional chemokine pathway. Taken together, our reported data on different CXCL16
expression in SPF vs GF mice and different iNKT cell proliferation in BFWT vs BFΔSPT
mice, suggest that the microbiome uses multiple, perhaps organism-specific mechanisms, for
keeping the numbers of iNKT cells in check.
The inhibitory bacterial glycosphingolipids further blur the conventional distinction between
self and non-self in terms of immune recognition. Evidence in this study suggests that the
host is strongly dependent on bacterial glycosphingolipid molecules for iNKT cell
homeostasis during development. Strikingly, our data show that an absence of these decisive
molecules in young GF and BFΔSPT mice has a lasting impact on the animals’ iNKT cell
homeostasis and causes an irreversible increase in their susceptibility to colitis. Our results
highlight the importance of sphingolipid-producing symbionts as a vital component of the
colonic microflora in early life, despite the fact that they are probably not the dominant
members of intestinal community at this age (Koenig et al., 2011; Yatsunenko et al., 2012).
It is also possible that the inhibitory bacterial sphingolipids are passed to the pups from
dams through milk. Nevertheless, although the enzymatic pathway required for production
of these glycosphingolipids is not encoded in the eukaryotic genome, we propose these
molecules—exemplified by GSL-Bf717—as prototypes for self-inhibitors of iNKT cells,
which is currently a scarcely explored yet important field in iNKT cell biology.
Our results also propose a novel paradigm for host–symbiont interactions. In host–pathogen
interactions, specific virulence factors directly target host cells and pathways with high
efficacy and result in specific immunologic response profiles. Herein we report that, in
contrast to pathogens, symbionts rather indirectly and subtly change the chemical
environment mediating host functions. Instead of active stimulation, which has a palpable
impact on host tissues, symbiosis factors—in this study glycosphingolipids—act silently,
passively and with relatively lower efficiency (since one molecule can occupy only one
CD1d groove). The overall mode of action by symbiosis factors is to regulate rather than to
stimulate. Ineptitude in stimulating the host immune system results in their evasion of host
immune surveillance and continual association with the host. The timing of symbiotic
molecules’ activity depends upon not microbes, but host physiological factors, such as
neonatal development and possibly immune stimulation. The lower efficiency of the
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symbiotic microbial molecules is compensated for by the bulk presence of these factors and
the huge numbers of microbes producing them (Ley et al., 2006; Zitomersky et al., 2011).
We propose that these attributes are essential for establishing a symbiotic relationship
between microbes and immune systems. It is tempting to speculate that other, still
unidentified symbiosis factors may function in a similar way to control host immune
homeostasis. In addition, although both are α-glycosphingolipids, GSL-Bf717 is the
diametrical opposite—in terms of function—of the sphingolipids produced by pathobiont
Sphingomonas species. This observation likely reflects the fine structural differences
between these molecules that result in dissimilar interactions with CD1d and the iNKT cell
receptor. More importantly, the opposite phenotypes reflect their profoundly different
relationships with the host and highlight a fundamental distinction between symbiosis and
pathogenesis.
Along with our studies of PSA, our evidence on the function of GSL-Bf717 offers new
insight into the functions of microbiota at the molecular level. PSA and GSL-Bf717 are
synthesized from the same bacterium (B. fragilis) but function differently: PSA facilitates
maturation of a balanced CD4+ T cell population, regardless of the host’s age, while GSL-
Bf717 is crucial to iNKT cells in a specific time window of life. These examples, although
thus far limited, strongly indicate that microbes deeply modulate host immune functions
with diverse effects. In addition, with their unusual inhibitory properties, GSL-Bf717 or
inhibitors yet to be discovered in the microbiota may offer promise as novel therapeutic
agents that can target the deleterious impact of iNKT cells in many human disorders (Braun
et al., 2010; Fuss et al., 2004; Matangkasombut et al., 2009; Peternel and Kastelan, 2009).
Experimental Procedures
Mice and cells
Swiss Webster mice maintained under SPF or GF conditions were purchased from Taconic
USA. C57BL/6 wild-type mice were purchased from the Jackson Laboratory. CD1d-
deficient mice (Smiley et al., 1997) were maintained in a SPF barrier facility at Harvard
Medical School. GF and mono-associated mice were bred and maintained in vinyl isolators
in the animal facility at Harvard Medical School. BMDCs were purified from mouse femurs
and cultured for 8 days in C-RPMI-10 with GM-CSF (20 ng/ml; Biosource). All procedures
were approved by the Harvard Medical Area Standing Committee on Animals.
Bacterial culture and mutant construction
B. fragilis strain NCTC 9343 was grown in flasks in an anaerobic chamber in rich medium
(An et al., 2011). Mutant strain BFΔSPT was constructed with a pNJR6 suicide vector; the
first 50 and last 94 nucleotides of gene BF2461 were retained, and the 1041 intervening
nucleotides were deleted (Comstock et al., 1999). The complemented strain C-delta,
maintained by erythromycin at 20 µg/ml, was constructed by expression of the full BF2461
gene on plasmid PFD340 and conjugation of the complementing plasmid to the BFΔSPT
mutant.
Co-housing experiment
GF females or young (10- to 14-day-old) GF pups and their dams were co-housed in an
isolator with BFWT mice (male for mating with GF females and female for the litters) for an
extended period. Effective colonization by BFWT bacteria was verified by examination of
stool samples from adult mice after 24 hours.
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B. fragilis lipid extraction
Total bacterial sphingolipids were purified from overnight anaerobic cultures of B. fragilis
(either BFWT or BFΔSPT) by a modified Bligh-Dyer method. Washed bacterial pellets were
stirred overnight in chloroform-methanol-water (1:2:0.8). The insoluble fraction was
precipitated; the liquid fraction was mixed with equal volumes of chloroform and water
(final composition, 1:1:0.9) and centrifuged for phase separation. The lower organic phase
was then collected, dried, and resuspended with the initial eluent. An open silica column was
used to fractionate the purified lipids with stepwise increases in the polarity of the eluents
(i.e., chloroform-methanol at ratios of 8:1 to 1:2). Each fraction was dried and resuspended
in chloroform. For differentiation of sphingolipids from non-sphingolipids, total lipids were
treated with 0.02 N NaOH for 30 min at 37°C before being subjected to thin-layer
chromatography. Lipid stocks (10 mg/ml) were prepared in chloroform, and working
solutions (1 mg/ml) were prepared in dimethyl sulfoxide.
Lipidomic profiling
To identify BFWT-specific sphingolipids, silica column–fractionated lipid fractions of the
BFWT and BFΔSPT strains were analyzed with reverse-phase HPLC-MS/MS (Agilent C18
column connected with Thermo Scientific LTQ-XL; gradients of water to methanol, 10:90
to 0:100) to identify spots present in BFWT but missing in BFΔSPT. Identified lipid species
of interest were purified by reverse-phase HPLC (Varian Prostar/Agilent C18 column) and
subjected to structural analysis.
CD1d tetramer loading and staining assay
For single lipid loading, phycoerythrin-tagged unloaded-mCD1d tetramers (1 µM; NIH
Tetramer Core Facility) were incubated overnight with 4 µM lipids in a 10-µl volume. After
three washes with PBS, the complex was resuspended in 10 µl of water. The solution (5 µl)
was used to stain iNKT cell hybridoma 24.7 or liver lymphocytes (1×105 cells), together
with FITC-labeled anti-CD3 (or TCR-β) (1 µl) and 7-AAD (5 µl) in total of 50-µl volume for
30 min at 4°C. Cells were then analyzed by flow cytometry. For competitive loading, the 1
µM empty tetramers were incubated with 4 µM PBS-44, in presence or absence of 12 µM
bacterial lipid GSL-Bf717 in a total volume of 6 µl PBS-0.1% Tween 20. After incubation
for 6–8 hours at 37°C in dark, each incubation mixture was washed and 15% of the mixture
was then used to stain iNKT cell hybridoma 24.7 as described above. PBS-57 and PBS-44
were provided by Dr. Gurdyal Besra, University of Birmingham, UK and Dr. Paul Savage,
Brigham Young University, USA, respectively.
BMDC–T cell co-culture assay
BMDCs (100 µl; 5 × 105 cells/ml) were pulsed with lipids in a 96-well plate in triplicate for
4 hours at 37°C. The wells were washed three times before addition of NKT hybridoma cells
of lines 24.7 (Behar et al., 1999), DN32.D3 (Lantz and Bendelac, 1994), and 14S6 (Behar et
al., 1999) in 200 µl volume (2.5 × 105 cells/ml). After 24 h at 37°C, culture supernatants
were subjected to IL-2 enzyme-linked immunosorbent assay (ELISA) (R&D). For
competition assays, bacterial lipids and KRN7000 (100 nM, Avanti Polar lipids) or β-GlcCer
(20 µM, C24:1 Glucosyl(β) Ceramide (d18:1/24:1(15Z)), Avanti Polar lipids) were pulsed
simultaneously with BMDCs.
In vivo cytokine inhibition assay
C57BL/6 wild-type or CD1d-knockout mice (6 weeks old) received one 100-µl
intraperitoneal injection of KRN7000 (1 µg/ml) or vehicle control (0.9% NaCl). In certain
groups, this injection was followed by an intraperitoneal injection of 100-µl (10 µg/ml)
bacterial lipid GSL-Bf717 or PE-Cers (estimated M.W.≈678). Each wild-type group
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included 4–8 mice; each CD1d-knockout group consisted of 2 mice. After 4 hours, serum
samples were prepared and subjected to ELISA for measurements of IFN-γ and IL-4.
Lipid treatment
GSL-Bf717 was purified and dissolved in ethanol at a concentration of 200 µg/ml. Before
treatment, the lipid sample was diluted in 0.9% NaCl to a concentration of 100 ng/30 µl. A
30-µl volume of the GSL-Bf717 solution or 0.9% NaCl was administered by oral gavage to
newborn BFΔSPT mice (in an isolator) 5 times during the first week of life; polyethylene
tubing with an inside diameter of 0.28 mm and an outside diameter of 0.61 mm (BD) was
used for gavage. For oxazolone colitis challenge studies, 6- to 8-week-old female mice were
used.
Statistical analysis
Two-tailed, non-paired Student’s t test or the two-tailed Mann Whitney test was used to
determine P values as specified in each figure legend. One-way ANOVA was performed for
multi-group comparison and reported in Table S2. Statistical significance was defined as P <
0.05. Detailed report for each test is listed in Table S2. Horizontal lines in dot plots represent
median values, and each dot represents one mouse. Whiskers in Box plots are minima and
maxima of the data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Symbiotic bacterial glycosphingolipids modulate host iNKT cell homeostasis.
• Early exposure to these lipids protects the host from later colitis challenges.
• These lipids inhibit iNKT cell proliferation.
• Treatment with microbial sphingolipids protects the host from colitis.
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Figure 1.
B. fragilis sphingolipids modulate homeostasis of colonic LP iNKT cells. Representative
FACS plots of iNKT cell gating are shown in (A). Total numbers of colonic LP iNKT cells
(B) and their percentages in CD3+ populations (C) were higher in GF and BFΔSPT than in
SPF and BFWT mice. B. fragilis mono-colonized mice had iNKT cell counts similar to
those of GF mice in lung (D), liver (E) and small intestine (F). Data in panels (B) and (C)
(days 21,42 and 63) were confirmed to have normal distribution by the KS normality test
with α=0.05, analyzed by the Student’s t test and are presented as mean ± SEM (standard
error of the mean); n≥3 for each group. Data in panels (D)–(F) were analyzed by the Mann
Whitney test. See also Fig. S1.
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Figure 2.
B. fragilis sphingolipids modulate host oxazolone-induced iNKT cell–mediated colitis
phenotype. Upon oxazolone colitis challenge, BFΔSPT mice had more severe weight loss
(A; n≥6; P values compare BFWT Oxa and BFΔSPT Oxa at days 3 and 4, respectively) and
higher cumulative histopathology scores (B) than did BFWT mice. In tissue explant
cultures, levels of IL-13 (C) and IL-4 (D) production in colonic tissue after oxazolone
challenge were higher in BFΔSPT mice than in BFWT mice although IL-1β production was
not (E). Data in (A) were confirmed to have normal distribution by the KS normality test
with α=0.05, analyzed by the Student’s t test and are presented as mean ± SEM; Data in
(B)–(E) were analyzed by the Mann Whitney test; n≥3 for each group; representative of 3
experiments. See also Fig. S2.
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Figure 3.
B. fragilis sphingolipids inhibit colonic LP iNKT cell proliferation during neonatal
development and restrict the accumulation of these cells in adult mice. Proliferation rates (A
and B; n≥3) were higher in GF and BFΔSPT mice than in SPF and BFWT mice at early
ages. Colonic LP iNKT cell counts were not restored in GF-WT(adu) mice, but GF-
WT(neo) mice had levels of colonic LP iNKT cell proliferation and total cell numbers
similar to those in BFWT mice (C and D). After oxazolone challenge, only GF-WT(adu)
mice had severe weight loss and high cumulative histopathology scores (E and F; n≥10; P
value in panel E compares BFWT and BF-WT(adu) mice at day 4). Data in (A) (days 8 and
12) and (E) were confirmed to have normal distribution by the KS normality test with
α=0.05, analyzed by the Student’s t test and are presented as mean ± SEM. MFI, mean
fluorescence intensity. Data in (B)–(D) and (F) were analyzed by the Mann Whitney test.
See also Fig. S3.
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Figure 4.
Chemical analysis of B. fragilis glycosphingolipid peak GSL-Bf717. Three distinct
sphingolipid clusters were identified in B. fragilis (A). None of these clusters activated
iNKT cells (B). GL-Cers was inhibitory to iNKT cell activation by KRN7000 in vitro (C).
Data in panel (B) are representative of 2 experiments, each with triplicates, and presented as
median ± range. Data in (C) complied three experiments (n≥6) and were confirmed to have
normal distribution by the KS normality test with α=0.05, analyzed by the Student’s t test
and are presented as mean ± SEM. P values compare KRN7000 + GSL-Bf717 (at ratios of
1:10 and 1:30) with KRN7000 alone (ratio 1:0). (D) GL-Cers had 5 chain-length variants,
C32–C36, and the C34 with M.W.=717.6 (m/z 716) was predominant. A peak from this
variant, GSL-Bf717, was characterized by MS/MS (E), HPAEC (F) and 1H-NMR (G) and
was found to have an α-galactosyl linkage. In (F), the hydrolyzed hexose head group co-
eluted with the spiked galactose standard (blue) at 12.6 min. In (H), the proposed molecular
configuration of GSL-Bf717 is shown for comparison with that of the prototypical agonist
KRN7000.
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Figure 5.
B. fragilis GSL-Bf717 inhibits iNKT cell activation. GSL-Bf717 did not activate iNKT cells
(A and C; data are representative of 2 independent experiments with each in triplicates) but
did inhibit iNKT cell activation by agonist KRN7000 in both hybridomas 24.7 and
DN32.D3 (B and D, data are representative of 2 independent experiments with each in
triplicates; P value compares KRN7000 + GSL-Bf717 at a 1:30 ratio with KRN7000 alone,
which is at ratio 1:0). GSL-Bf717 also inhibited activation by agonist β-GlcCer (right
columns in B; P values compare β-GlcCer + GSL-Bf717 at ratios 40:1 and 20:1 with β-
GlcCer alone, which is at ratio 1:0). The loading efficiency of PBS-44 to empty CD1d
tetramer (phycoerythrin-labeled) was decreased significantly in presence of GSL-Bf717 as
evidenced by the lowered MFI of CD1d tetramer-stained iNKT cells (E); n=4. GSL-Bf717
reduced serum levels of IFN-γ (F) and IL-4 (G) released by KRN7000-stimulated iNKT
cells in vivo. 100% production was defined as the level of cytokines produced in KRN7000
only-treated mice; n≥4. Data in (A)–(F) are presented as median ± range. Data in (B), (D)–
(F) were analyzed by the Mann Whitney test. Data in (G) were confirmed to have normal
distribution by the KS normality test with α=0.05, analyzed by the Student’s t test and are
presented as mean ± SEM. See also Fig. S4.
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Figure 6.
GSL-Bf717 treatment of neonatal BFΔSPT mice restores colonic iNKT cell homeostasis and
protects mice from colitis in adulthood. GSL-Bf717-treated mice had lower Ki-67
expression at 8-day (A; n≥4) and lower total counts of colonic LP iNKT cells at 8 weeks (B;
n≥6). These mice were protected against the oxazolone challenge, with less weight loss (C;
P values compare the two groups at days 1 and 4) and lower cumulative histopathology
scores (D). Data are representative of 2 independent experiments; n=6 for each group. Data
in (A), (B) and (D) were analyzed by the Mann Whitney test. Data in (C) were confirmed to
have normal distribution by the KS normality test with α=0.05, analyzed by the Student’s t
test and are presented as mean ± SEM.
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